Strides Pharma gets USFDA EIR for its Bangalore flagship facility
![Strides Pharma gets USFDA EIR for its Bangalore flagship facility Strides Pharma gets USFDA EIR for its Bangalore flagship facility](https://business.medicaldialogues.in/h-upload/2020/03/11/125386-usfda-inspection-1.jpg)
Bangalore: Strides Pharma has announced that the Company's flagship facility (KRS Gardens) in Bangalore which was inspected by the USFDA in March 2020, has received the Establishment Inspection Report (EIR), thereby confirming the successful closure of the inspections.
Strides, listed on the BSE Limited and National Stock Exchange of India Limited , is a global pharmaceutical company headquartered in Bangalore, India.
The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets.
The Company's global manufacturing sites are located in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi and United States-Florida. The Company focusses on "difficult to manufacture" products that are sold in over 100 countries.
Read also: Strides Get USFDA Nod For Tetracycline Hydrochloride Capsules
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd